PROCESS DEVELOPMENT OF TELACEBEC FOR TUBERCULOSIS

Midwest Research Institute, Kansas City MO

Investigators

Abstract

The overall objective of this project is for the contractor to support the chemistry, manufacturing, and controls (CMC) development of Telacebec (Q203), to treat Tuberculosis. Rare Diseases